• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基线肌肉减少症与肝癌患者对治疗无反应、肝功能失代偿和高死亡率相关。

Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.

机构信息

Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koom, Egypt.

Department of Diagnostic Medical Imaging and Interventional Radiology; National Liver Institute, Menoufia University, Shebeen El-Koom, Egypt.

出版信息

Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3285-3290. doi: 10.31557/APJCP.2020.21.11.3285.

DOI:10.31557/APJCP.2020.21.11.3285
PMID:33247686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8033124/
Abstract

OBJECTIVE

hepatocellular carcinoma (HCC) is a dreadful complication of liver cirrhosis. Aim was to study the effect of sarcopenia on the survival in patients with HCC.

METHODS

we included 262 patients and were followed up for 12 months. Sarcopenia was calculated by skeletal muscle index (SMI). Sarcopenia was defined by SMI ≤39 cm2/m2 for women and ≤50 cm2/m2 for men.

RESULTS

patients with sarcopenia (n= 113, 43.1%) were older, mainly males, Child-Pugh class B and smokers. Patients with sarcopenia had lower survival than those without (10.09 vs. 11.72 months). Survival was also lower in Barcelona clinic liver cancer stage C than B and A (9.02 vs. 11.21 vs. 11.89 months). Age and sarcopenia were hazardous of mortality (p <0.05). There was statistically significant difference of serial SMI in patients without baseline sarcopenia unlike patients with baseline sarcopenia. On follow up patients with sarcopenia had higher incidence of ascites (45% vs. 20.4%), spontaneous bacterial peritonitis (21.7% vs. 11.6%), hepatic encephalopathy (28% vs. 11.5%) and bleeding (22.9% vs. 12.7%). Totally patients with sarcopenia had higher incidence of progressive HCC (39% vs. 25.5%).

CONCLUSION

Sarcopenia is associated with lack of response to therapy, liver decompensation and higher mortality in hepatocellular carcinoma patients.
.

摘要

目的

肝细胞癌(HCC)是肝硬化的一种严重并发症。本研究旨在探讨肌肉减少症对 HCC 患者生存的影响。

方法

我们纳入了 262 例患者,并进行了 12 个月的随访。通过骨骼肌指数(SMI)计算肌肉减少症。女性肌肉减少症定义为 SMI≤39cm2/m2,男性为 SMI≤50cm2/m2。

结果

肌肉减少症患者(n=113,43.1%)年龄较大,主要为男性,Child-Pugh 分级为 B 级和吸烟者。与无肌肉减少症患者相比,有肌肉减少症患者的生存率较低(10.09 个月比 11.72 个月)。巴塞罗那临床肝癌分期 C 期患者的生存率低于 B 期和 A 期(9.02 个月比 11.21 个月比 11.89 个月)。年龄和肌肉减少症是死亡的危险因素(p<0.05)。与无基线肌肉减少症的患者相比,基线无肌肉减少症的患者的 SMI 连续值存在统计学差异。在随访中,有肌肉减少症的患者腹水(45%比 20.4%)、自发性细菌性腹膜炎(21.7%比 11.6%)、肝性脑病(28%比 11.5%)和出血(22.9%比 12.7%)的发生率更高。总的来说,有肌肉减少症的患者进展性 HCC 的发生率更高(39%比 25.5%)。

结论

肌肉减少症与 HCC 患者对治疗无反应、肝功能失代偿和更高的死亡率有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/62b1a47918ed/APJCP-21-3285-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/d26902d736c9/APJCP-21-3285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/d45eb73607b4/APJCP-21-3285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/1a4fdebf15da/APJCP-21-3285-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/62b1a47918ed/APJCP-21-3285-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/d26902d736c9/APJCP-21-3285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/d45eb73607b4/APJCP-21-3285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/1a4fdebf15da/APJCP-21-3285-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43e6/8033124/62b1a47918ed/APJCP-21-3285-g004.jpg

相似文献

1
Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.基线肌肉减少症与肝癌患者对治疗无反应、肝功能失代偿和高死亡率相关。
Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3285-3290. doi: 10.31557/APJCP.2020.21.11.3285.
2
Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.肌少症作为不可切除肝细胞癌患者行单纯经动脉栓塞治疗后生存的预测因子。
PLoS One. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371. eCollection 2020.
3
Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.肌肉减少症、BMI 和炎症生物标志物对接受抗 PD-1 抗体治疗的晚期肝细胞癌患者生存的影响。
Am J Clin Oncol. 2021 Feb 1;44(2):74-81. doi: 10.1097/COC.0000000000000787.
4
Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume.肌肉减少症影响肝细胞癌患者的预后:肝脏功能储备和肿瘤相关因素在骨骼肌量减少中的作用。
Nutrients. 2017 Sep 22;9(10):1054. doi: 10.3390/nu9101054.
5
Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis.肌肉减少症预示着初诊肝细胞癌患者的生存率降低。
Ann Hepatol. 2017;16(1):107-114. doi: 10.5604/16652681.1226821.
6
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌中预肌少症的影响。
PLoS One. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812. eCollection 2018.
7
Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.肝细胞癌患者死亡的风险因素:印度尼西亚的一项多中心研究。
Curr Probl Cancer. 2020 Feb;44(1):100480. doi: 10.1016/j.currproblcancer.2019.05.003. Epub 2019 May 20.
8
Sarcopenia as a Predictive Factor for Recurrence of Hepatocellular Carcinoma Following Radiofrequency Ablation.肌肉减少症作为射频消融术后肝细胞癌复发的预测因素。
Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1143-1150. doi: 10.31557/APJCP.2023.24.4.1143.
9
Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.骨骼肌量迅速下降预示经导管肝动脉内治疗的肝细胞癌预后不良。
BMC Cancer. 2018 Jul 24;18(1):756. doi: 10.1186/s12885-018-4673-2.
10
"Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study"."骨骼肌减少症和肌肉内脂肪沉积与印度尼西亚肝细胞癌患者的不良预后相关:一项回顾性研究"。
BMC Gastroenterol. 2019 Dec 30;19(1):229. doi: 10.1186/s12876-019-1152-4.

引用本文的文献

1
ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma.ALBI-肌少症评分作为肝细胞癌治疗结果的预测指标
Sci Rep. 2025 Apr 26;15(1):14621. doi: 10.1038/s41598-025-97295-7.
2
The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.钬-166经动脉放射性栓塞术后肌肉减少症的恶化可作为晚期肝细胞癌患者3个月疾病进展的预测指标:一项初步研究。
J Pers Med. 2024 May 11;14(5):511. doi: 10.3390/jpm14050511.
3
Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk.

本文引用的文献

1
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.肌少症评估对接受治疗的肝细胞癌患者的临床影响。
J Gastroenterol. 2020 Oct;55(10):927-943. doi: 10.1007/s00535-020-01711-w. Epub 2020 Aug 3.
2
Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.肌少症作为不可切除肝细胞癌患者行单纯经动脉栓塞治疗后生存的预测因子。
PLoS One. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371. eCollection 2020.
3
Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.
肝细胞癌患者肌肉减少症的超声评估:一种更快、更简便的高危患者检测方法。
Diagnostics (Basel). 2024 Feb 8;14(4):371. doi: 10.3390/diagnostics14040371.
4
Prognostic Nutritional Index Correlates with Liver Function and Prognosis in Chronic Liver Disease Patients.预后营养指数与慢性肝病患者的肝功能及预后相关。
Diagnostics (Basel). 2023 Dec 25;14(1):49. doi: 10.3390/diagnostics14010049.
5
Prevalence of Sarcopenia in Africa: A Systematic Review.非洲肌肉减少症的患病率:系统评价。
Clin Interv Aging. 2023 Jul 4;18:1021-1035. doi: 10.2147/CIA.S407917. eCollection 2023.
6
Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis.肝细胞癌患者中肌肉减少症的患病率:一项系统评价和荟萃分析。
Oncol Lett. 2023 May 18;26(1):283. doi: 10.3892/ol.2023.13869. eCollection 2023 Jul.
7
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.非酒精性脂肪性肝病/代谢相关脂肪性肝病中的肌少症骨量减少症:慢性肝病中一个被低估的临床问题。
Int J Mol Sci. 2023 Apr 19;24(8):7517. doi: 10.3390/ijms24087517.
8
Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.癌症患者治疗前肌少症:癌症治疗期间患病率和预测价值的最新荟萃分析。
Nutrients. 2023 Feb 27;15(5):1193. doi: 10.3390/nu15051193.
9
Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.恶液质指数对接受系统化疗的晚期肝细胞癌患者的预后意义。
Sci Rep. 2022 May 10;12(1):7647. doi: 10.1038/s41598-022-11736-1.
10
Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions.肝细胞癌中的肌肉减少症:当前的认识和未来的方向。
World J Gastroenterol. 2022 Jan 28;28(4):432-448. doi: 10.3748/wjg.v28.i4.432.
综述文章:肝硬化患者的营养不良/肌肉减少症和衰弱。
Aliment Pharmacol Ther. 2020 Jan;51(1):64-77. doi: 10.1111/apt.15571. Epub 2019 Nov 8.
4
Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies.肌肉减少症是接受经动脉化疗栓塞术(TACE)治疗肝恶性肿瘤患者的不良预后因素。
Cancers (Basel). 2019 Oct 8;11(10):1503. doi: 10.3390/cancers11101503.
5
Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma.改良白蛋白-胆红素-TNM 评分作为评估肝细胞癌患者预后模型的验证
World J Hepatol. 2019 Jun 27;11(6):542-552. doi: 10.4254/wjh.v11.i6.542.
6
Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis.肝硬化患者骨骼肌异常的临床意义。
Dig Liver Dis. 2019 Nov;51(11):1493-1499. doi: 10.1016/j.dld.2019.05.034. Epub 2019 Jun 17.
7
Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma.经动脉化疗栓塞期间骨骼肌体积减少预示着肝细胞癌患者的预后不良。
Hepatol Res. 2019 Jul;49(7):778-786. doi: 10.1111/hepr.13331. Epub 2019 Apr 25.
8
Association Between Sarcopenia and AFP Level in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.肌少症与肝癌肝移植患者 AFP 水平的相关性。
J Surg Res. 2019 Jun;238:10-15. doi: 10.1016/j.jss.2019.01.007. Epub 2019 Feb 2.
9
Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.骨骼肌量迅速下降预示经导管肝动脉内治疗的肝细胞癌预后不良。
BMC Cancer. 2018 Jul 24;18(1):756. doi: 10.1186/s12885-018-4673-2.
10
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌中预肌少症的影响。
PLoS One. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812. eCollection 2018.